Search

Search Constraints

You searched for: Author/Creator Terragna, Carolina

Search Results

1. Baseline cluster of differentiation 22 fluorescent intensity correlates with patient outcome after Inotuzumab Ozogamicin treatment. Issue 4 (5th June 2022)

2. Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. Issue 12 (December 2020)

3. Bortezomib‐ and thalidomide‐induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. Issue 12 (17th September 2014)

4. Bortezomib‐based therapy combined with high cut‐off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment. Issue 7 (July 2015)

5. Circulating cell‐free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre‐analytical biases. Issue 1 (19th October 2022)

6. Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia. Issue 1 (15th October 2021)

7. Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant. Issue 4 (7th May 2021)

8. Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens. Issue 9 (1st September 2016)

9. The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30‐year experience. Issue 10 (23rd July 2021)